
Viridian Therapeutics VRDN
$ 30.86
2.25%
Viridian Therapeutics EV/EBITDA Ratio | VRDN
Annual EV/EBITDA Ratio Viridian Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -8.14 | -3.73 | -3.25 | -6.13 | -2.37 | -0.6 | - | - | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -0.6 | -8.14 | -4.04 |
EV/EBITDA Ratio of other stocks in the Biotechnology industry
| Issuer | EV/EBITDA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Translate Bio, Inc.
TBIO
|
350 | - | - | $ 2.81 B | ||
|
Trillium Therapeutics Inc.
TRIL
|
-14 | - | - | $ 1.94 B | ||
|
Urovant Sciences Ltd.
UROV
|
-1.91 K | - | - | $ 532 M | ||
|
Acceleron Pharma Inc.
XLRN
|
-47 | - | - | $ 10.9 B | ||
|
Zealand Pharma A/S
ZEAL
|
-0.823 | - | 0.52 % | $ 821 M | ||
|
Zogenix, Inc.
ZGNX
|
-4.47 | - | -4.97 % | $ 664 M | ||
|
Yunhong International
ZGYH
|
44 | - | 0.10 % | $ 92.2 M | ||
|
ZIOPHARM Oncology, Inc.
ZIOP
|
-8.58 | - | -7.58 % | $ 264 M | ||
|
Xenon Pharmaceuticals
XENE
|
-6.03 | $ 41.4 | 2.35 % | $ 3.28 B | ||
|
Leap Therapeutics
LPTX
|
0.106 | - | 368.57 % | $ 41.9 M | ||
|
Zymeworks
ZYME
|
-3.7 | $ 31.45 | 2.08 % | $ 1.62 B | ||
|
Adial Pharmaceuticals
ADIL
|
0.407 | $ 3.15 | -35.42 % | $ 2.11 M | ||
|
ADMA Biologics
ADMA
|
19.2 | $ 12.67 | -0.98 % | $ 3.02 B | ||
|
Cortexyme
CRTX
|
-2.13 | - | -1.05 % | $ 67.1 M | ||
|
Burford Capital Limited
BUR
|
24.7 | $ 3.66 | -1.35 % | $ 802 M | ||
|
Daré Bioscience
DARE
|
-1.83 | $ 0.69 | 1.75 % | $ 7.71 M | ||
|
Fate Therapeutics
FATE
|
-1.04 | $ 1.78 | -8.51 % | $ 211 M | ||
|
Greenwich LifeSciences
GLSI
|
-19.8 | $ 16.05 | -2.85 % | $ 217 M | ||
|
Halozyme Therapeutics
HALO
|
25 | $ 103.0 | 0.08 % | $ 12.3 B | ||
|
Hutchison China MediTech Limited
HCM
|
-481 | $ 15.34 | 0.1 % | $ 13.2 B | ||
|
Aptorum Group Limited
APM
|
29.7 | - | - | $ 5.72 M | ||
|
iBio
IBIO
|
-2.85 | $ 0.78 | -1.89 % | $ 81.2 M | ||
|
Kodiak Sciences
KOD
|
-9.31 | $ 108.01 | 0.85 % | $ 5.75 B | ||
|
Karyopharm Therapeutics
KPTI
|
-3.77 | $ 0.02 | -54.5 % | $ 219 | ||
|
FSD Pharma
HUGE
|
-0.271 | - | 5743.5 % | $ 69.7 M | ||
|
BioAtla
BCAB
|
-0.888 | $ 1.74 | 0.64 % | $ 102 M | ||
|
Catalyst Pharmaceuticals
CPRX
|
9.61 | - | - | $ 3.85 B | ||
|
UroGen Pharma Ltd.
URGN
|
-8.98 | $ 25.32 | -3.78 % | $ 1.22 B | ||
|
Catalyst Biosciences
CBIO
|
70.6 | $ 13.91 | 1.9 % | $ 1.24 B | ||
|
ARCA biopharma
ABIO
|
0.248 | - | 1052.0 % | $ 415 M | ||
|
Acasti Pharma
ACST
|
1.28 | - | 4.01 % | $ 150 M | ||
|
ADiTx Therapeutics
ADTX
|
-0.487 | - | - | $ 374 | ||
|
Aeterna Zentaris
AEZS
|
-0.963 | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
-0.164 | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
0.111 | - | - | $ 1.01 B | ||
|
AIkido Pharma
AIKI
|
-45.5 | - | 1.93 % | $ 17.4 M | ||
|
Aileron Therapeutics
ALRN
|
-0.0795 | - | 10.36 % | $ 9.8 M | ||
|
AlloVir
ALVR
|
1.19 | - | 4.14 % | $ 49.1 M | ||
|
Apellis Pharmaceuticals
APLS
|
52.9 | - | - | $ 5.18 B | ||
|
Athira Pharma
ATHA
|
0.0485 | - | - | $ 269 M | ||
|
AVROBIO
AVRO
|
2.95 | - | 1083.1 % | $ 745 M | ||
|
AstraZeneca PLC
AZN
|
3.06 | - | - | $ 96.9 B | ||
|
Brainstorm Cell Therapeutics
BCLI
|
-1.13 | - | -2.5 % | $ 5.88 M | ||
|
BeiGene, Ltd.
BGNE
|
-1.22 | - | 0.49 % | $ 251 B | ||
|
EyePoint Pharmaceuticals
EYPT
|
0.177 | $ 0.39 | 9.06 % | $ 28.6 K | ||
|
Bio-Path Holdings
BPTH
|
-0.864 | - | - | $ 100 K | ||
|
Cara Therapeutics
CARA
|
0.36 | - | -3.03 % | $ 260 M | ||
|
ChromaDex Corporation
CDXC
|
-2.07 | - | -0.88 % | $ 598 M | ||
|
Caladrius Biosciences
CLBS
|
0.709 | - | -16.75 % | $ 25.8 M |